Disposition of 520711 shares by Foresite Capital Management Iv, Llc of Kinnate BiopharmaInc at 2.5879 subject to Rule 16b-3
KNTEDelisted Stock | USD 2.96 0.27 8.36% |
About 61% of Kinnate Biopharma's investor base is looking to short. The analysis of current outlook of investing in Kinnate Biopharma suggests that many traders are alarmed regarding Kinnate Biopharma's prospects. The current market sentiment, together with Kinnate Biopharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Kinnate Biopharma stock news signals to limit their universe of possible portfolio assets.
Kinnate |
Filed transaction by Kinnate BiopharmaInc 10 Percent Owner. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at news.google.com
Kinnate Biopharma Fundamental Analysis
We analyze Kinnate Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kinnate Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kinnate Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Kinnate Biopharma is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Kinnate Biopharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kinnate Biopharma stock to make a market-neutral strategy. Peer analysis of Kinnate Biopharma could also be used in its relative valuation, which is a method of valuing Kinnate Biopharma by comparing valuation metrics with similar companies.
Peers
Kinnate Biopharma Related Equities
KRON | Kronos Bio | 2.17 | ||||
BOLT | Bolt Biotherapeutics | 1.96 | ||||
PASG | Passage Bio | 1.54 | ||||
LRMR | Larimar Therapeutics | 1.00 | ||||
STOK | Stoke Therapeutics | 1.60 | ||||
SLRN | ACELYRIN, INC | 2.11 | ||||
GLUE | Monte Rosa | 2.22 | ||||
KROS | Keros Therapeutics | 2.32 | ||||
KZR | Kezar Life | 2.92 | ||||
ERAS | Erasca | 3.05 | ||||
EWTX | Edgewise Therapeutics | 3.10 | ||||
WINT | Windtree Therapeutics | 3.13 | ||||
GBIO | Generation Bio | 3.60 | ||||
DSGN | Design Therapeutics | 3.70 | ||||
IPSC | Century Therapeutics | 3.70 | ||||
CCCC | C4 Therapeutics | 5.25 | ||||
PALI | Palisade Bio | 5.65 | ||||
SRZN | Surrozen | 5.95 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Kinnate Stock
If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data |